The genetic testing services market size is projected to grow from US$ 3,425.23 million in 2022 to US$ 10,556.29 million by 2030; it is estimated to record a CAGR of 15.1% during 2022–2030.
Market Insights and Analyst View:
Genetic testing, also called DNA testing or genetic analysis, is a medical and scientific procedure that involves examining and analyzing an individual's DNA to gain insights into the individual's genetic makeup and genetic information. Genetic testing can reveal specific genetic variations, mutations, or alterations within an individual's genome, providing information about their genetic predispositions, inherited traits, risk of certain diseases, and more. Genetic testing is conducted for various purposes, including diagnosing genetic disorders, assessing disease risk, identifying carrier status for inherited conditions, understanding ancestry and genealogy, and guiding personalized medical treatments. Genetic testing generally involves the analysis of a sample of genetic material, such as blood, saliva, buccal swabs, or tissue samples, to examine the individual's DNA.
Growth Drivers:
Personalized medicine is the field that utilizes patients' genetic and environmental data to deliver optimal healthcare. It is based on the principle that every patient is unique and requires individualistic pharmacological treatment. Since it is a rapidly evolving area, it is presently incorporated into several healthcare systems. The successful completion of the Human Genome Project (HGP) in 2003 and the fast-decreasing human genome sequencing costs encouraged the development of a new medical approach, which is called personalized medicine. With an expanding repository of personalized data at the molecular level, molecular diagnostics companies are exceptionally positioned to unlock value. The awareness of personalized medicine has increased since the commencement of the Precision Medicine Initiative, announced by Barack Obama in 2015. Not only in the US but also in Germany, personalized medicine, better known as individualized medicine (IM), has gained traction. By the end of 2010, the German Federal Ministry of Education and Research (BMBF) named personalized medicine as one of the six priorities. It introduced the Action Plan called "Individualized Medicine." Moreover, the 100,000 Genomes Project is also strengthening the National Health Service's position as one of the most advanced healthcare systems in the world. Also, the project is consolidating the foundation for personalized medicine, and this, in turn, contributes to the genetic testing services market growth.
Large-scale drug discovery is a key to increasing the viability and usefulness of personalized medicines for the diagnosis of diseases and disorders. Genomics is one of the fastest-growing divisions of medical science. It is driving a paradigm shift in the research methodology of a disease, as well as diagnosing and treating illness. Genetic testing has been extensively used in pharmacogenomics, also known as drug-gene testing. It helps in accelerating drug discovery and its development.
France also developed a national plan for personalized medicine known as "Genomic Medicine France 2025." The program was presented to Prime Minister Manuel Valls by Yves Lévy, President of the National Alliance for Life and Health Sciences—Aviesan and CEO of Inserm, in June 2016. It appeals to healthcare and manufacturing firms to pilot genomic sequencing platforms. The plan was supported by the government and launched with a public financing of US$ 760.8 million (€ 670 million) in 2020 for genomics and personalized medicine programs. It is expected to place France as a leader among countries involved in genomic medicine within the next ten years.
April 2023 marked the 20th anniversary of the completion of the Human Genome Project, a major milestone in the history of science by the National Human Genome Research Institute. Now, new research shows that precision prescribing using genetic testing has ultimately reached a global tipping point for adoption. Published by Cambridge University Press, the peer-reviewed research examines the maturation of critical factors required for the use of clinical genetics at scale. These advancements pave the way for supporting genome-informed clinical decision-making to be recognized as the new standard of care. Genetically informed prescribing offers one of the realistic mechanisms to successfully reduce the overall costs of the healthcare system and improve individual patient care. Genetic testing encourages the adoption of a personalized medicine approach by understanding the science behind the disease, the impact of treatment, and the development of therapies for specific individual characteristics. It also helps healthcare personnel make informed decisions about disease diagnosis, treatment, and prevention by employing genetic testing results, leading to enhanced patient outcomes.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Genetic Testing Services Market: Strategic Insights
Market Size Value in US$ 3,425.23 million in 2022 Market Size Value by US$ 10,556.29 million by 2030 Growth rate CAGR of 15.1% from 2022 to 2030 Forecast Period 2022-2030 Base Year 2022
Akshay
Have a question?
Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Genetic Testing Services Market: Strategic Insights
| Market Size Value in | US$ 3,425.23 million in 2022 |
| Market Size Value by | US$ 10,556.29 million by 2030 |
| Growth rate | CAGR of 15.1% from 2022 to 2030 |
| Forecast Period | 2022-2030 |
| Base Year | 2022 |
Akshay
Have a question?
Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Report Segmentation and Scope:
The genetic testing services market is segmented on the basis of service type, disease, service provider, and geography. On the basis of service type, the genetic testing services market is categorized into predictive testing, carrier testing, prenatal testing, newborn screening, diagnostic genetic testing, and others. The genetic testing services market, based on disease, is segmented into cancer, cardiovascular diseases, metabolic diseases, and other diseases. The genetic testing services market, based on service providers, is classified into general testing services and liquid biopsy-based CGP, MRD, and MCED services. The genetic testing services market, based on geography, is segmented into North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, the UAE, South Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
Segmental Analysis:
The genetic testing services market, based on service type, is segmented into prenatal testing, predictive testing, carrier testing, newborn screening, diagnostic genetic testing, and others. In 2022, the diagnostic genetic testing segment held the largest share of the market and is projected to register the highest CAGR in the market from 2022 to 2030. Diagnostic testing is performed to identify a specific genetic or chromosomal disease. This test detects a specific gene alteration but is often unable to determine disease severity or age of onset. A mutation in a single gene may result in many diseases, for example, Down's syndrome, cystic fibrosis, and Huntington's disease. Genetic testing often confirms a diagnosis when a specific condition is suspected based on physical signs and symptoms. Diagnostic testing can be done before birth or at any time during a person's life. The results of diagnostic tests can influence a person's choices about healthcare and disease or disorder management. Advancements in genetic testing have transformed the risk assessment and diagnostic landscape for many hereditary and genetic diseases. Advanced tools introduced to test genetic diseases allow diagnostic service providers to better understand and detect multiple illnesses, including rare diseases. In oncology, genetic variations can determine whether a patient is at an increased risk for a specific type of cancer. For instance, patients with a family history of breast cancer may be tested for genetic risk factors that correlate with a high risk of breast cancer.
Genetic Testing Services Market, by Service Type – 2022 and 2030
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
Based on the disease, the genetic testing services market is categorized into cancer, cardiovascular diseases, metabolic diseases, and other diseases. The cancer segment held the largest share of the market in 2022 and is projected to register the highest CAGR from 2022 to 2030.
Based on service providers, the genetic testing services market is segmented into general testing services and liquid biopsy-based CGP, MRD, and MCED services. In 2022, the general testing services segment held the largest share of the market and is anticipated to register the highest CAGR during 2022–2030.
Regional Analysis:
The genetic testing services market is primarily divided into North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. North America captured a major share of the market in 2022, followed by Europe. European countries have undertaken several initiatives to increase awareness among people about the advantages of genetic testing. The ultimate aim is to ensure that all facets of genetic testing are of high quality, thus providing precise and reliable results for the patients. In Europe, Germany held a significant share of the genetic testing services market. Medical genetics has become a vital part of clinical practice. It has provided doctors with a valued diagnostic and an analytical pre-symptomatic tool, which they can use more effectively to manage patients' diseases and even take preventive actions. As per a study titled "Awareness and Knowledge of Rare Diseases in German Dentists, Dental Specialists, and Oral and Maxillofacial Surgeons," published in 2022, rare diseases affect about four million patients in the country. Moreover, the rising prevalence of rare diseases and the development of custom-made testing kits for niche therapeutic areas, along with the adoption of genetic testing kits, are aiding the rapid growth of the market.
As per Globocan 2020, ~69,697 new breast cancer cases were reported in 2020 in Germany, representing 11.1% of all registered cancer cases. It caused 20,579 fatalities, and the five-year prevalence rate of breast cancer in all ages was 707.38 per 100,000 population. Nearly 16% of women with triple-negative breast cancer carry a BRCA mutation in Germany. In 2018, the government of the country announced a strategy to include BRCA genetic testing in Germany's national cancer plan, which was initiated in 2008 with the goal of ensuring women with high genetic risk of breast cancer are legally entitled to intensified screening and risk-reducing options. The increasing focus by the government to regulate and create awareness regarding genetic tests has effectively resulted in the faster adoption of tests across the country.
In Germany, noninvasive prenatal testing became available as a publicly reimbursed test in 2022. In addition, the introduction of reimbursement programs, increasing demand for efficient treatment options, and implementation of innovative technologies in research centers are expected to drive market expansion in the country. Growing awareness about the advantages of genetic testing, knowledge among healthcare professionals, and the rise in consumer spending on healthcare propels the genetic testing services market.
Industry Developments and Future Opportunities:
Several initiatives taken by key market players operational in the global genetic testing services market are listed below:
- In October 2023, 23andMe Holding Co announced a nonexclusive data license collaboration with GSK plc, which enables GSK to conduct drug target discovery and other research using the 23andMe database.
- In April 2023, Ambry Genetics Corp collaborated with LifeStrands Genomics to offer clinical genetic testing services in Singapore. Both companies will support the Clinical Implementation Pilots (CIPs) for Phase II of Singapore's National Precision Medicine (NPM) program.
- In April 2022, CENTOGENE released FilterTool, a web-based application for interpreting genetic data. FilterTool connects with CentoCloud to effectively show, filter, select, and categorize pertinent genetic variations found through Next Generation Sequencing (NGS) data processing.
Competitive Landscape and Key Companies:
Laboratory Corporation of America Holdings; Illumina, Inc.; F. Hoffmann-La Roche Ltd; Exact Sciences Corp (Genomic Health); Quest Diagnostics Incorporated; NeoGenomics Laboratories, Inc.; Eurofins Scientific; Centogene AG; Ambry Genetics; 23andMe; and Bio-Rad Laboratories are among the top 10 players genetic testing companies in the genetic testing services market. These companies focus on presenting new high-tech products, technological advancements, and geographic expansions to meet the growing consumer demand worldwide.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Service Type, Disease, Service Provider, and Geography
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The global genetic testing services market, by services type, is segmented into predictive testing, carrier testing, prenatal testing, diagnostic genetic testing, new-born screening, and others. The diagnostic genetic testing is expected to dominate the market owing to it is helpful to people who have a family history of a treatable genetic disorder and display no signs of illness.
Genetic testing services are medical tests that analyze an individual's DNA to identify potential genetic variations or mutations that may be associated with certain health conditions or diseases. These tests can provide valuable information about an individual's risk for developing certain diseases, as well as help guide personalized medical treatment and management plans.
The global genetic testing services market majorly consists of the players such as Laboratory Corporation of America Holdings, F. Hoffmann-La Roche Ltd, Illumina, Inc., Quest Diagnostics Incorporated, Exact Sciences Corp (Genomic Health), NeoGenomics Laboratories, Inc., Eurofins Scientific, Ambry Genetics, Centogene AG, and 23andMe, Inc., Bio-Rad Laboratories
The factors driving the market include rising prevalence of genetic diseases and increasing awareness and acceptance of personalized medicines. However, social and ethical implications of genetic testing hinder the market growth.
The List of Companies - Genetic Testing Services Market
- Laboratory Corporation of America Holdings
- F. Hoffmann-La Roche Ltd
- Illumina, Inc.
- Quest Diagnostics Incorporated
- Exact Sciences Corp (Genomic Health)
- NeoGenomics Laboratories, Inc.
- Eurofins Scientific
- Ambry Genetics
- Centogene AG
- 23andMe, Inc.
- Bio-Rad Laboratories
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Trends and growth analysis reports related to Genetic Testing Services Market
Dec 2023
Bioprocessing Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Instruments, and Consumables and Accessories), Scale of Operation (Commercial Operations and Clinical Operations), Process (Downstream Bioprocess and Upstream Bioprocess), Application (Monoclonal Antibodies, Vaccines, Recombinant Protein, Cell and Gene Therapy, and Others), End User (Biopharmaceutical Companies, Contract Manufacturing Organization, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
Dec 2023
Bioproduction Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product (Biologics and Biosimilars, Vaccines, Cell and Gene Therapies, Nucleic Acid Therapeutics, and Others), Application (Rheumatoid Arthritis, Hematological Disorders, Cancer, Diabetes, Cardiovascular Diseases, and Others), Equipment (Upstream Equipment, Downstream Equipment, Bioreactors, and Consumables and Accessories), End User (Biopharmaceutical Companies, Contract Manufacturing Organizations, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Dec 2023
ELISA Diagnostic Test Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Adoption (Human and Veterinary), Test Type (Sandwich ELISA, Indirect ELISA, Competitive ELISA, and Multiple & Portable ELISA), Application (Autoimmune Diseases, Infectious Diseases, Cancer Diagnosis, Protein Quantification, and Others), End User (Hospitals & Diagnostic Centers, Pharmaceutical & Biotechnology Companies, Veterinary Hospitals & Diagnostic Laboratories, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
Dec 2023
Swine Diagnostics Market
Size and Forecasts (2022 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product Type [Immunoassays Kits, PCR Kits, Hemagglutination Inhibition (HI), and Others], Sample Type (Blood, Oral Fluids, Nasal Swabs, Tissue Samples, and Others), Disease [African Swine Fever (ASF)/Classical Swine Fever (CSF), Respiratory Diseases, Porcine Circovirus, Porcine Epidemic Diarrhea, Swine Dysentery, and Others], End User (Veterinary Hospitals, Veterinary Clinics, and Other End Users), and Geography
Dec 2023
Microbial Identification Methods Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Method (Genotypic, Phenotypic, and Proteotypic), Type (Bacterial Identification System, Microbial Enumeration System, Bacterial Resistance Identification Systems, Microbiology Analyzer, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and Latin America)
Dec 2023
Biopharmaceuticals Market
Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Monoclonal Antibodies, Recombinant Vaccines, Conventional Vaccines, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Recombinant Hormones, Recombinant Enzymes, Cell & Gene Therapies, Cytokines/Interferon/Interleukins, and Others) and Application (Oncology, Inflammatory & Infectious Disease, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders & Growth Failure, Cardiovascular Diseases, Neurological Diseases, and Others)
Dec 2023
GMP Cell Therapy Consumables Market
Forecast to 2028 - COVID-19 Impact and Global Analysis by Product (Kits, Reagents/Molecular Biology Reagents, Growth Factors/Cytokines and Interleukins, and Others), Cell Therapy (NK Cell Therapy, Stem Cell Therapy, T-Cell Therapy, and Others), Process (Cell Collection and Characterization/Sorting and Separation, Cell Culture and Expansion/Preparation, Cryopreservation, Cell Processing and Formulation, Cell Isolation and Activation, Cell Distribution/Handling, Process Monitoring and Control/Readministration/Quality Assurance, and Others), and End Use (Clinical, Commercial, and Research)
Dec 2023